Larimar Therapeutics (LRMR) Competitors $3.03 -0.07 (-2.26%) As of 02:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LRMR vs. KURA, RLAY, MRVI, STOK, BCAX, VALN, ARVN, MAZE, OPT, and RGNXShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Kura Oncology (KURA), Relay Therapeutics (RLAY), Maravai LifeSciences (MRVI), Stoke Therapeutics (STOK), Bicara Therapeutics (BCAX), Valneva (VALN), Arvinas (ARVN), Maze Therapeutics (MAZE), Opthea (OPT), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Its Competitors Kura Oncology Relay Therapeutics Maravai LifeSciences Stoke Therapeutics Bicara Therapeutics Valneva Arvinas Maze Therapeutics Opthea REGENXBIO Larimar Therapeutics (NASDAQ:LRMR) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends. Do insiders & institutionals have more ownership in LRMR or KURA? 91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 6.4% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer LRMR or KURA? Larimar Therapeutics currently has a consensus price target of $19.67, indicating a potential upside of 551.21%. Kura Oncology has a consensus price target of $24.50, indicating a potential upside of 262.43%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93 Is LRMR or KURA more profitable? Larimar Therapeutics' return on equity of -35.87% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Larimar TherapeuticsN/A -35.87% -32.37% Kura Oncology N/A -44.09%-39.57% Does the media favor LRMR or KURA? In the previous week, Kura Oncology had 4 more articles in the media than Larimar Therapeutics. MarketBeat recorded 10 mentions for Kura Oncology and 6 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.18 beat Kura Oncology's score of 0.98 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, LRMR or KURA? Larimar Therapeutics has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLarimar TherapeuticsN/AN/A-$36.95M-$1.49-2.03Kura Oncology$67.99M8.61-$152.63M-$2.10-3.22 Does the MarketBeat Community favor LRMR or KURA? Kura Oncology received 395 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 71.88% of users gave Larimar Therapeutics an outperform vote while only 69.78% of users gave Kura Oncology an outperform vote. CompanyUnderperformOutperformLarimar TherapeuticsOutperform Votes4671.88% Underperform Votes1828.13% Kura OncologyOutperform Votes44169.78% Underperform Votes19130.22% Which has more volatility & risk, LRMR or KURA? Larimar Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. SummaryLarimar Therapeutics beats Kura Oncology on 11 of the 17 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$193.37M$6.93B$5.60B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-2.638.8727.2520.01Price / SalesN/A263.25412.71157.94Price / CashN/A65.8538.2534.64Price / Book1.626.617.124.70Net Income-$36.95M$144.20M$3.24B$248.05M7 Day Performance22.76%3.88%2.75%2.62%1 Month Performance45.19%11.26%9.00%6.32%1 Year Performance-68.61%3.96%31.41%13.78% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics2.7814 of 5 stars$3.03-2.3%$19.67+549.1%-66.8%$194.01MN/A-2.6330Positive NewsShort Interest ↓High Trading VolumeKURAKura Oncology4.4521 of 5 stars$6.30+10.7%$24.50+288.9%-67.8%$545.42M$67.99M-2.67130Analyst RevisionRLAYRelay Therapeutics2.219 of 5 stars$3.18+6.0%$17.67+455.6%-53.8%$545.20M$7.68M-1.22330Positive NewsGap UpMRVIMaravai LifeSciences4.0526 of 5 stars$2.13-5.3%$6.64+211.7%-71.9%$542.43M$241.86M-1.30610Options VolumeSTOKStoke Therapeutics3.9033 of 5 stars$9.91+3.9%$23.20+134.1%-27.4%$541.06M$190.91M-4.72100Positive NewsAnalyst RevisionBCAXBicara Therapeutics2.3373 of 5 stars$9.90+7.0%$31.86+221.8%N/A$539.91MN/A0.0032Analyst RevisionGap UpHigh Trading VolumeVALNValneva2.6126 of 5 stars$6.41+0.2%$15.50+141.8%-24.1%$536.11M$186.06M-49.31700Short Interest ↓ARVNArvinas4.0092 of 5 stars$7.33+1.8%$20.29+176.8%-70.8%$535.02M$426.90M-2.65420Analyst RevisionHigh Trading VolumeMAZEMaze TherapeuticsN/A$12.10+20.9%$25.67+112.1%N/A$529.94M$167.50M0.00121OPTOpthea0.8245 of 5 stars$3.41+7.2%$1.33-60.9%+36.4%$524.84M$87.67K0.008News CoverageGap UpRGNXREGENXBIO4.2428 of 5 stars$10.35+16.9%$31.63+205.6%-24.9%$519.16M$156.72M-2.06370Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Kura Oncology Alternatives Relay Therapeutics Alternatives Maravai LifeSciences Alternatives Stoke Therapeutics Alternatives Bicara Therapeutics Alternatives Valneva Alternatives Arvinas Alternatives Maze Therapeutics Alternatives Opthea Alternatives REGENXBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LRMR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
